ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. ( Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study […]